drugset
drugset / Trial / NCT00276913

A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors

NCT00276913 ↗

Phase 1 Completed 30 enrolled Synta Pharmaceuticals Corp.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Primary Objectives: * To determine the safety, toxicity and the maximum tolerated dose (MTD) of intravenous STA-5312 when administered weekly (3 of 4 weeks) to subjects with advanced or metastatic solid tumors. * To determine the pharmacokinetics of STA-5312. Secondary Objective: • To assess antitumor activity of STA-5312 administration.

Timeline

Start
2004-06
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject ROSABULIN Small molecule 6 mg/m2 Intravenous
Subject ROSABULIN Small molecule 8 mg/m2 Intravenous

Indications

No indication recorded.